IL277174B1 - Therapeutic combination of 1–4 bb agonists with anti-CD20 antibodies - Google Patents
Therapeutic combination of 1–4 bb agonists with anti-CD20 antibodiesInfo
- Publication number
- IL277174B1 IL277174B1 IL277174A IL27717420A IL277174B1 IL 277174 B1 IL277174 B1 IL 277174B1 IL 277174 A IL277174 A IL 277174A IL 27717420 A IL27717420 A IL 27717420A IL 277174 B1 IL277174 B1 IL 277174B1
- Authority
- IL
- Israel
- Prior art keywords
- seq
- amino acid
- acid sequence
- agonist
- cdr
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (13)
1. A 4-1BB (CD137) agonist for use in a method for treating a B-cell proliferative disorder, wherein the 4-1BB agonist is used in combination with an anti-CD20 antibody selected from rituximab or obinutuzumab, wherein: (a) said B-cell proliferative disorder is selected from the group consisting of Non-Hodgkin lymphoma (NHL), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle-cell lymphoma (MCL), marginal zone lymphoma (MZL), Multiple myeloma (MM) and Hodgkin lymphoma (HL); and (b) said 4-1BB agonist is an antigen binding molecule comprising (i) one antigen binding domain capable of specific binding to CD19, (ii) a first and a second polypeptide that are linked to each other by a disulfide bond, and (iii) an IgG1 Fc domain comprising the amino acid substitutions L234A, L235A and P329G (EU numbering); and (c) said first polypeptide comprises two ectodomains of 4-1BBL comprising the amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO: 6, SEQ ID NO:7 and SEQ ID NO:8 that are connected to each other by a peptide linker and said second polypeptide comprises one ectodomain of 4-1BBL comprising the amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO: 6, SEQ ID NO:7 and SEQ ID NO:8.
2. The 4-1BB agonist for use in a method of claim 1, wherein the 4-1BB agonist and the anti-CD20 antibody are administered together in a single composition or administered separately in two different compositions.
3. The 4-1BB agonist for use in a method of claims 1 or 2, wherein the ectodomains of 4-1BBL comprise the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:5.
4. The 4-1BB agonist for use in a method of any one of claims 1 to 3, wherein the antigen binding domain capable of specific binding to CD19 comprises (a) a heavy chain variable region (VHCD19) comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:9, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:10, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:11, and a light chain variable region (VLCD19) comprising (iv) CDR-L1 comprising the amino acid - 136 - 277174/ sequence of SEQ ID NO:12, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:13, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:14, or (b) a heavy chain variable region (VHCD19) comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:15, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:16, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:17, and a light chain variable region (VLCD19) comprising (iv) CDR-L1 comprising the amino acid sequence of SEQ ID NO:18, (v) CDR-L2 comprising the amino acid sequence of SEQ ID NO:19, and (vi) CDR-L3 comprising the amino acid sequence of SEQ ID NO:20.
5. The 4-1BB agonist for use in a method of any one of claims 1 to 4, wherein the antigen binding domain capable of specific binding to CD19 comprises a heavy chain variable region (VHCD19) comprising an amino acid sequence of SEQ ID NO:21 and a light chain variable region (VLCD19) comprising an amino acid sequence of SEQ ID NO:22 or wherein the antigen binding domain capable of specific binding to CD19 comprises a heavy chain variable region (VHCD19) comprising an amino acid sequence of SEQ ID NO:23 and a light chain variable region (VLCD19) comprising an amino acid sequence of SEQ ID NO:24.
6. The 4-1BB agonist for use in a method of any one of claims 1 to 5, wherein (a) the antigen binding domain capable of specific binding to CD19 is a Fab, and (b) said first polypeptide as defined in claim 1b(ii) comprises the amino acid sequence selected from the group consisting of SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31 and SEQ ID NO:32.
7. The 4-1BB agonist for use in a method of any one of claims 1 to 6, wherein the 4-1BB agonist is an antigen binding molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:47, a first light chain comprising the amino acid sequence of SEQ ID NO:48, a second heavy chain comprising the amino acid sequence of SEQ ID NO:41 and a second light chain comprising the amino acid sequence of SEQ ID NO:42.
8. The 4-1BB agonist for use in a method of any one of claims 1 to 7, wherein the combination is administered concomitant at intervals from about one week to three weeks.
9. The 4-1BB agonist for use in a method of any one of claims 1 to 8, wherein a pretreatment with an Type II anti-CD20 antibody, preferably obinutuzumab, is performed prior to the combination treatment, wherein the period of time between the pretreatment and the combination treatment is sufficient for the reduction of B-cells in the individual in response to the Type II anti-CD20 antibody, preferably obinutuzumab.
10. A pharmaceutical composition comprising - 137 - 277174/ - a 4-1BB agonist as defined in claim 1, and - an anti-CD20 antibody selected from rituximab or obinutuzumab, wherein the 4-1BB agonist and the anti-CD20 antibody are administered together in a single composition.
11. The pharmaceutical composition of claim 10 for use as medicament.
12. The pharmaceutical composition of claims 10 or 11 for use in the treatment of a B-cell proliferative disorder selected from the group consisting of Non-Hodgkin lymphoma (NHL), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle-cell lymphoma (MCL), marginal zone lymphoma (MZL), Multiple myeloma (MM) and Hodgkin lymphoma (HL).
13. The pharmaceutical composition of any one of claims 10 to 12, wherein the 4-1BB agonist is an antigen binding molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:47, a first light chain comprising the amino acid sequence of SEQ ID NO:48, a second heavy chain comprising the amino acid sequence of SEQ ID NO:and a second light chain comprising the amino acid sequence of SEQ ID NO:42.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18161435 | 2018-03-13 | ||
| PCT/EP2019/055946 WO2019175071A1 (en) | 2018-03-13 | 2019-03-11 | Therapeutic combination of 4-1 bb agonists with anti-cd20 antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL277174A IL277174A (en) | 2020-10-29 |
| IL277174B1 true IL277174B1 (en) | 2025-08-01 |
| IL277174B2 IL277174B2 (en) | 2025-12-01 |
Family
ID=61691234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL277174A IL277174B2 (en) | 2018-03-13 | 2019-03-11 | Therapeutic combination of 1–4 bb agonists with anti-CD20 antibodies |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210163617A1 (en) |
| EP (1) | EP3765489B1 (en) |
| JP (1) | JP7159332B2 (en) |
| KR (1) | KR102836393B1 (en) |
| CN (2) | CN119074915A (en) |
| AU (1) | AU2019236372B2 (en) |
| BR (1) | BR112020015568A2 (en) |
| CA (1) | CA3092002A1 (en) |
| ES (1) | ES2998140T3 (en) |
| IL (1) | IL277174B2 (en) |
| MX (1) | MX2020009468A (en) |
| PL (1) | PL3765489T3 (en) |
| TW (1) | TWI828662B (en) |
| WO (1) | WO2019175071A1 (en) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2788979T3 (en) | 2014-11-14 | 2020-10-23 | Hoffmann La Roche | Antigen-binding molecules comprising a ligand trimer of the TNF family |
| JP6996979B2 (en) | 2015-03-31 | 2022-02-04 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Antigen-binding molecule containing trimer TNF family ligand |
| MY206406A (en) | 2015-10-02 | 2024-12-16 | Hoffmann La Roche | Bispecific antibodies specific for a costimulatory tnf receptor |
| JP7125400B2 (en) | 2016-12-19 | 2022-08-24 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Combination therapy with targeted 4-1BB (CD137) agonists |
| KR102692708B1 (en) | 2016-12-20 | 2024-08-07 | 에프. 호프만-라 로슈 아게 | Combination therapy of anti-CD20/anti-CD3 bispecific antibodies and 4-1BB (CD137) agonists |
| CA3047070A1 (en) | 2017-01-03 | 2018-07-12 | F.Hoffmann-La Roche Ag | Bispecific antigen binding molecules comprising anti-4-1bb clone 20h4.9 |
| WO2018178055A1 (en) | 2017-03-29 | 2018-10-04 | F. Hoffmann-La Roche Ag | Bispecific antigen binding molecule for a costimulatory tnf receptor |
| CN110402255B (en) | 2017-04-04 | 2022-12-02 | 豪夫迈·罗氏有限公司 | A novel bispecific antigen-binding molecule capable of specifically binding CD40 and FAP |
| CA3052532A1 (en) | 2017-04-05 | 2018-10-11 | F. Hoffmann-La Roche Ag | Bispecific antibodies specifically binding to pd1 and lag3 |
| TWI841551B (en) | 2018-03-13 | 2024-05-11 | 瑞士商赫孚孟拉羅股份公司 | Combination therapy with targeted 4-1bb (cd137) agonists |
| CR20200459A (en) | 2018-04-13 | 2020-11-11 | Hoffmann La Roche | Her2-targeting antigen binding molecules comprising 4-1bbl |
| US11242396B2 (en) | 2018-10-01 | 2022-02-08 | Hoffmann-La Roche Inc. | Bispecific antigen binding molecules comprising anti-FAP clone 212 |
| CR20210326A (en) | 2018-12-21 | 2021-09-10 | Hoffmann La Roche | CD28 ANTIGEN BINDING AGONIST MOLECULES ACTING ON THE TUMOR |
| AR121706A1 (en) | 2020-04-01 | 2022-06-29 | Hoffmann La Roche | OX40 AND FAP-TARGETED BSPECIFIC ANTIGEN-BINDING MOLECULES |
| CR20220637A (en) | 2020-06-19 | 2023-01-31 | Hoffmann La Roche | ANTIBODIES THAT BIND CD3 AND CD19 |
| CN115197329A (en) * | 2021-04-13 | 2022-10-18 | 晶源生物医药(苏州)有限公司 | 4-1BB agonist and preparation method and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016075278A1 (en) * | 2014-11-14 | 2016-05-19 | F. Hoffmann-La Roche Ag | Antigen binding molecules comprising a tnf family ligand trimer |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2808353C2 (en) | 1977-04-18 | 1984-01-19 | Hitachi Metals, Ltd., Tokyo | Earring |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| JP3101690B2 (en) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | Modifications of or for denatured antibodies |
| FI903489A7 (en) | 1988-11-11 | 1990-07-10 | Medical Res Council | Ligands containing one moiety, receptors containing these ligands, methods for their preparation and uses of the ligands and receptors |
| DE3920358A1 (en) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| ES2136092T3 (en) | 1991-09-23 | 1999-11-16 | Medical Res Council | PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES. |
| FI941572L (en) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Combination and method of use of anti-erbB-2 monoclonal antibodies |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| JP2002506353A (en) | 1997-06-24 | 2002-02-26 | ジェネンテック・インコーポレーテッド | Methods and compositions for galactosylated glycoproteins |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| DE19742706B4 (en) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | lipocalin muteins |
| CA2307166A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
| WO1999029888A1 (en) | 1997-12-05 | 1999-06-17 | The Scripps Research Institute | Humanization of murine antibody |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| CA2323757C (en) | 1998-04-02 | 2011-08-02 | Genentech, Inc. | Antibody variants and fragments thereof |
| JP4334141B2 (en) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | Engineering glycosylation of antibodies to improve antibody-dependent cytotoxicity |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| KR100797667B1 (en) | 1999-10-04 | 2008-01-23 | 메디카고 인코포레이티드 | How to regulate transcription of foreign genes |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| PT2857516T (en) | 2000-04-11 | 2017-08-28 | Genentech Inc | Multivalent antibodies and uses therefor |
| EP1332209B1 (en) | 2000-09-08 | 2009-11-11 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
| EP1423510A4 (en) | 2001-08-03 | 2005-06-01 | Glycart Biotechnology Ag | ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED CELL CYTOTOXICITY DEPENDENT OF ANTIBODIES |
| PL213948B1 (en) | 2001-10-25 | 2013-05-31 | Genentech Inc | Glycoprotein compositions |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| US7432063B2 (en) | 2002-02-14 | 2008-10-07 | Kalobios Pharmaceuticals, Inc. | Methods for affinity maturation |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| KR100944575B1 (en) | 2002-10-17 | 2010-02-25 | 젠맵 에이/에스 | Human monoclonal antibodies against CD20 |
| HUE035898T2 (en) | 2002-12-16 | 2018-05-28 | Genentech Inc | Immunoglobulin variants and uses thereof |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| AU2004242846A1 (en) | 2003-05-31 | 2004-12-09 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders |
| WO2005019255A1 (en) | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| HUE038955T2 (en) | 2003-11-05 | 2018-12-28 | Roche Glycart Ag | Antigen binding molecules with increased Fc receptor binding affinity and effector function |
| DK1691833T3 (en) | 2003-11-28 | 2010-05-03 | Micromet Ag | Compositions comprising polypeptides |
| US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
| CN1961003B (en) | 2004-03-31 | 2013-03-27 | 健泰科生物技术公司 | Humanized anti-TGF-beta antibodies |
| WO2005100402A1 (en) | 2004-04-13 | 2005-10-27 | F.Hoffmann-La Roche Ag | Anti-p-selectin antibodies |
| EP1740946B1 (en) | 2004-04-20 | 2013-11-06 | Genmab A/S | Human monoclonal antibodies against cd20 |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| TR201808537T4 (en) | 2004-09-23 | 2018-07-23 | Genentech Inc | Cysteine modified antibodies and conjugates. |
| JO3000B1 (en) | 2004-10-20 | 2016-09-05 | Genentech Inc | Antibody Formulations. |
| AU2006290433B2 (en) | 2005-08-26 | 2012-06-07 | Roche Glycart Ag | Modified antigen binding molecules with altered cell signaling activity |
| US8236308B2 (en) | 2005-10-11 | 2012-08-07 | Micromet Ag | Composition comprising cross-species-specific antibodies and uses thereof |
| EP2471816A1 (en) | 2006-08-30 | 2012-07-04 | Genentech, Inc. | Multispecific antibodies |
| WO2008119567A2 (en) | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific cd3-epsilon binding domain |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| PL2604693T3 (en) | 2008-07-21 | 2016-09-30 | TNFSF single chain molecules | |
| PE20171512A1 (en) | 2010-08-13 | 2017-10-20 | Roche Glycart Ag | ANTI-FAP ANTIBODIES |
| LT2691417T (en) | 2011-03-29 | 2018-10-25 | Roche Glycart Ag | Antibody fc variants |
| KR102069397B1 (en) | 2012-02-15 | 2020-01-22 | 에프. 호프만-라 로슈 아게 | Fc-receptor based affinity chromatography |
| CA2904806C (en) | 2013-04-29 | 2021-11-23 | F. Hoffmann-La Roche Ag | Human fcrn-binding modified antibodies and methods of use |
| WO2015179236A1 (en) * | 2014-05-21 | 2015-11-26 | Pfizer Inc. | Combination of an anti-ccr4 antibody and a 4-1bb agonist for treating cancer |
| PL3177643T3 (en) * | 2014-08-04 | 2019-09-30 | F.Hoffmann-La Roche Ag | Bispecific t cell activating antigen binding molecules |
| JP6996979B2 (en) * | 2015-03-31 | 2022-02-04 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Antigen-binding molecule containing trimer TNF family ligand |
| AU2016335842A1 (en) * | 2015-10-07 | 2018-04-12 | Obi Pharma, Inc. | Novel carbohydrate antibodies, pharmaceutical compositions and uses thereof |
| EP3231813A1 (en) * | 2016-03-29 | 2017-10-18 | F. Hoffmann-La Roche AG | Trimeric costimulatory tnf family ligand-containing antigen binding molecules |
| WO2018017649A1 (en) * | 2016-07-19 | 2018-01-25 | Unum Therapeutics Inc. | Use of antibody-coupled t cell receptor (actr) with multiple anti-cancer antibodies in cancer treatment |
| KR102692708B1 (en) * | 2016-12-20 | 2024-08-07 | 에프. 호프만-라 로슈 아게 | Combination therapy of anti-CD20/anti-CD3 bispecific antibodies and 4-1BB (CD137) agonists |
-
2019
- 2019-03-11 PL PL19709056.6T patent/PL3765489T3/en unknown
- 2019-03-11 JP JP2020547215A patent/JP7159332B2/en active Active
- 2019-03-11 MX MX2020009468A patent/MX2020009468A/en unknown
- 2019-03-11 KR KR1020207029096A patent/KR102836393B1/en active Active
- 2019-03-11 EP EP19709056.6A patent/EP3765489B1/en active Active
- 2019-03-11 AU AU2019236372A patent/AU2019236372B2/en active Active
- 2019-03-11 BR BR112020015568-3A patent/BR112020015568A2/en not_active Application Discontinuation
- 2019-03-11 CN CN202411106240.XA patent/CN119074915A/en active Pending
- 2019-03-11 CN CN201980011952.4A patent/CN111683961A/en active Pending
- 2019-03-11 CA CA3092002A patent/CA3092002A1/en active Pending
- 2019-03-11 IL IL277174A patent/IL277174B2/en unknown
- 2019-03-11 ES ES19709056T patent/ES2998140T3/en active Active
- 2019-03-11 WO PCT/EP2019/055946 patent/WO2019175071A1/en not_active Ceased
- 2019-03-12 TW TW108108151A patent/TWI828662B/en active
-
2020
- 2020-09-10 US US17/017,576 patent/US20210163617A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016075278A1 (en) * | 2014-11-14 | 2016-05-19 | F. Hoffmann-La Roche Ag | Antigen binding molecules comprising a tnf family ligand trimer |
Non-Patent Citations (2)
| Title |
|---|
| KOHRT, HOLBROOK E., ET AL., IMMUNOMODULATION OF NK CELLS THROUGH 4-1BB (CD137) TO IMPROVE THE ANTI-LYMPHOMA ACTIVITY OF RITUXIMAB: ANTIBODY-BASED ANTI-LYMPHOMA SYNERGY., 31 December 2010 (2010-12-31) * |
| LIU R. ET AL.,, EFFICIENT INHIBITION OF HUMAN B-CELL LYMPHOMA IN SCID MICE BY SYNERGISTIC ANTITUMOR EFFECT OF HUMAN 4-1BB LIGAND/ANTI-CD20 FUSION PROTEIN AND ANTI-CD3/ANTI-CD20 DIABODIES., 30 June 2010 (2010-06-30) * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20210163617A1 (en) | 2021-06-03 |
| TWI828662B (en) | 2024-01-11 |
| CA3092002A1 (en) | 2019-09-19 |
| ES2998140T3 (en) | 2025-02-19 |
| KR102836393B1 (en) | 2025-07-22 |
| AU2019236372A1 (en) | 2020-07-30 |
| JP2021515782A (en) | 2021-06-24 |
| KR20200132913A (en) | 2020-11-25 |
| TW202003552A (en) | 2020-01-16 |
| EP3765489B1 (en) | 2024-10-16 |
| IL277174B2 (en) | 2025-12-01 |
| IL277174A (en) | 2020-10-29 |
| EP3765489C0 (en) | 2024-10-16 |
| CN119074915A (en) | 2024-12-06 |
| CN111683961A (en) | 2020-09-18 |
| EP3765489A1 (en) | 2021-01-20 |
| PL3765489T3 (en) | 2025-02-10 |
| JP7159332B2 (en) | 2022-10-24 |
| BR112020015568A2 (en) | 2020-12-29 |
| MX2020009468A (en) | 2020-10-22 |
| AU2019236372B2 (en) | 2024-06-20 |
| WO2019175071A1 (en) | 2019-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020504723A5 (en) | ||
| US12600779B2 (en) | LAG-3-binding molecules and methods of use thereof | |
| JP7551693B2 (en) | Variable region of NKp46 binding protein | |
| US20230357404A1 (en) | Pd-1-binding molecules and methods of use thereof | |
| US12331119B2 (en) | Modified Fc fragment, antibody comprising same, and application thereof | |
| RU2018126297A (en) | ANTIBODIES AIMED AT CD32B AND WAYS TO USE THEM | |
| JP2022507295A5 (en) | ||
| CA3089230A1 (en) | Trispecific antigen binding proteins | |
| JP2021524478A5 (en) | ||
| JP2022515258A5 (en) | ||
| JP2023547506A5 (en) | ||
| AU2021411581A9 (en) | Antibodies to tnfr2 and uses thereof | |
| JP2025508317A5 (en) | ||
| CA3136255A1 (en) | Dosing regimens of bispecific cd123 x cd3 diabodies in the treatment of hematologic malignancies | |
| FI3681911T3 (en) | Binding proteins to the human thrombin receptor, par4 | |
| JP7192042B2 (en) | LAG-3 binding molecules and methods of use thereof | |
| CA2986953C (en) | Lag-3-binding molecules and methods of use thereof | |
| NZ778352A (en) | Tumor-targeted agonistic cd28 antigen binding molecules | |
| NZ778352B2 (en) | Tumor-targeted agonistic cd28 antigen binding molecules | |
| RU2024119658A (en) | AGONISTIC ANTIBODIES TO LTBR AND BISPECIFIC ANTIBODIES CONTAINING THEM | |
| RU2021116831A (en) | HUMANIZED ANTI-SIRPα ANTIBODIES | |
| EA041483B1 (en) | LAG-3 BINDING MOLECULES AND METHODS FOR THEIR APPLICATION | |
| BR112017026330B1 (en) | LAG-3 BINDING MOLECULE COMPRISING A LAG-3 BINDING DOMAIN CAPABLE OF BINDING BOTH HUMAN AND CYNOMOLGUS MONKEY LAG-3 | |
| RU2021112776A (en) | HUMANIZED AND AFINITY MATURE ANTIBODIES AGAINST FcRH5 AND METHODS FOR THEIR APPLICATION | |
| NZ767672A (en) | Antigen binding molecules comprising a tnf family ligand trimer |